Related Experiment Videos
Risk factors for cardiac morbidity and mortality in dialysis patients
1Division of Nephrology, Memorial University, St. John's Newfoundland, Canada.
Insights
Patients starting end-stage renal disease therapy often have cardiac conditions like heart failure and hypertrophy. These, along with uremic factors, significantly impact prognosis and mortality risk.
Area of Science:
- Nephrology
- Cardiology
- Internal Medicine
Background:
- Cardiac disease is common in patients initiating end-stage renal disease (ESRD) therapy.
- Congestive heart failure, ischemic heart disease, and left ventricular hypertrophy are prevalent.
- These conditions are independent predictors of adverse outcomes.
Purpose of the Study:
- To outline the clinical and echocardiographic manifestations of cardiac disease in ESRD patients.
- To identify prognostic indicators and reversible risk factors.
- To understand the relationship between hypertension, heart failure, and mortality.
Main Methods:
- Review of clinical and echocardiographic data in patients starting ESRD therapy.
- Analysis of prognostic indicators including cardiac conditions and uremic factors.
- Assessment of risk factors such as inadequate dialysis, anemia, hypoalbuminemia, hypocalcemia, hypertension, and hypotension.
Main Results:
- Congestive heart failure, ischemic heart disease, systolic dysfunction, concentric left ventricular hypertrophy, and left ventricular dilatation are significant adverse prognostic indicators.
- These indicators are independent of age, diabetes mellitus, and smoking.
- Potentially reversible risk factors include inadequate dialysis, anemia, hypoalbuminemia, and hypocalcemia.
- Hypertension predisposes to congestive heart failure; subsequent hypotension predicts mortality.
Conclusions:
- Cardiac disease is a major concern for patients beginning ESRD therapy.
- Several clinical factors, including uremic-related issues, significantly influence patient prognosis.
- Management of hypertension and uremic complications is crucial for improving outcomes in ESRD patients.
Abstract:
Clinical and echocardiographic manifestations of cardiac disease are frequently present in patients starting end-stage renal disease therapy. Congestive heart failure, ischemic heart disease, systolic dysfunction, concentric left ventricular hypertrophy, and left ventricular dilatation are significant, adverse prognostic indicators, independent of age, diabetes mellitus, and smoking. Risk factors related to the uremic state, which are potentially reversible, include inadequate dialysis, anemia, hypoalbuminemia and hypocalcemia. Hypertension predisposes patients to congestive heart failure, following the development of which hypotension becomes an independent predictor of mortality.